Compare · RVTY vs SEER
RVTY vs SEER
Side-by-side comparison of Revvity Inc. (RVTY) and Seer Inc. (SEER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVTY and SEER operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $16.97B, about 147.4x SEER ($115.2M).
- Over the past year, RVTY is up 62.4% and SEER is down 7.5% - RVTY leads by 69.9 points.
- RVTY has been more active in the news (7 items in the past 4 weeks vs 3 for SEER).
- RVTY has more recent analyst coverage (23 ratings vs 8 for SEER).
- Company
- Revvity Inc.
- Seer Inc.
- Price
- $152.62-1.34%
- $2.03-0.73%
- Market cap
- $16.97B
- $115.2M
- 1M return
- +4.01%
- +6.01%
- 1Y return
- +62.38%
- -7.52%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 7
- 3
- Recent ratings
- 23
- 8
Seer Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
Latest SEER
- SEC Form 3 filed by Seer Inc.
- Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
- Seer Announces CFO Transition
- SEC Form 8-K filed by Seer Inc.
- Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
- Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of Directors
- PRESIDENT & CFO Horn David R. sold $14,809 worth of shares (7,309 units at $2.03), decreasing direct ownership by 1% to 486,650 units (SEC Form 4) to cover taxes
- Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
- SEC Form 10-Q filed by Seer Inc.
- Seer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits